For research and educational purposes only. Not medical advice.

IGF-1 DES Reference

Educational, not medical advice reference for IGF-1 DES: Growth Factor; regulatory status, evidence posture, source review, and schedule notes.…

Reference summary

IGF-1 DES was developed primarily as a cell-culture research reagent. There is no published human clinical program for DES-IGF-1. Community framing extrapolates from recombinant IGF-1 pharmacology, with an emphasis on lower IGFBP affinity producing more localized tissue effects.

Regulatory and posture

Categories
Growth Factor
Aliases
des(1-3)IGF-1, DES IGF-1, Truncated IGF-1
Evidence posture
preclinical - WADA-prohibited. No published human clinical program for IGF-1 DES. Hypoglycemia, tissue overgrowth, and anti-doping sanction are the principal documented risks, similar to IGF-1 LR3.
Regulatory status
No FDA-approved IGF-1 DES drug label. IGF-1 DES is a truncated IGF-1 analog lacking the first three N-terminal amino acids, studied in cell-culture research and sold in gray-market research-vial form. WADA prohibits IGF-1 and its analogs under category S2 at all times.
Content review status
research reference

Selected public sources

Related tools